share_log

Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

Benzinga ·  Aug 7, 2023 21:07

Cantor Fitzgerald analyst Charles Duncan maintains Vaxart (NASDAQ:VXRT) with a Overweight and lowers the price target from $6 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment